Ide Smets (@SmetsIde) header
Ide Smets (@SmetsIde) profile picture

Neurologist@ErasMS_Rdam. Past ECTRIMS Clinical Fellow at Barts-MS London. Mainly talking 🧠-sense!

Joined February 2020
Photo by Ide Smets (@SmetsIde)Photo by Ide Smets (@SmetsIde)Photo by Ide Smets (@SmetsIde)Photo by Ide Smets (@SmetsIde)Photo by Ide Smets (@SmetsIde)Photo by Ide Smets (@SmetsIde)Photo by Ide Smets (@SmetsIde)Photo by Ide Smets (@SmetsIde)Photo by Ide Smets (@SmetsIde)Photo by Ide Smets (@SmetsIde)
Not all MS drugs are created equal! In MS Center ErasMS gebruiken we daarom vanaf nu de Nederlandse versie van de #clinicspeak medicatie keuzetool. Vrij beschikbaar voor alle MS centra en pmMS. DM voor een visitekaartje! clinicspeak.com/dmt/nl
2
217
Very 🔥 debate with @XtineLebrunF and @drBWillekens on a late breaking topic: should we start treating radiologically isolated syndrome? A struggle between biology and disease, that needs to be addressed by new RIS criteria. @ECTRIMS
1
1
4
In simulated MS cohorts, lesion detection algorithms argue to be disease-modifying by detection more lesions, triggering early treatment switches and preventing disability. Nice feature or necessary add-on intervention? multiple-sclerosis-research.…
1
4
Rituximab (anti-CD20) is a more potent MS drug than dimethyl fumarate. The bigger question: is it better than the more costly ocrelizumab? Three possible answers: an official, a real and a right one. Which one do you prefer?@the_MSBlog multiple-sclerosis-research.…
3
9
There’s no exit strategy for pwMS on anti-CD20 atm. Some argue there’s no need to exit, some argue to extend intervals and we argue to stop anti-CD20 after 4 infusion cycli. Do you agree? journals.sagepub.com/doi/10.… @ErasMS_Rdam
2
3
20
The position of aHSCT in the MS treatment landscape is a source of debate, and for many pwMS it’s unclear who can benefit. In early aggressive MS it’s clear, but for progressive MS the risk/benefit profile of aHSCT shifts. @the_MSBlog multiple-sclerosis-research.…
2
2
During clincics, we are often too much focused on drugs, and forget to mention the second most-effective MS treatment: exercise. To compensate, I discuss my insights together with @themsguide in this podcast. #brainhealth open.spotify.com/episode/0bK…
1
5
Many pwMS need to gain a new expertise: overcoming administrative hurdles to gain access to crucial healthcare services such as rehab. In the UK this is the red tape, in the Netherlands a purple crocodile. Do you have any in your pool? multiple-sclerosis-research.… @ErasMS_Rdam
1
3
Many pwMS struggle with DMT decisions when they have new lesions on brain MRI without new symptoms. Two attempts to better explain this clinical-MRI paradox: the topographical model of MS and road traffic. Do you stop for groceries at night? @the_MSBlog multiple-sclerosis-research.…
1
2
4
Serum NfL Z-scores instead of raw cut-offs are much better at predicting inflammatory disease activity in pwMS. An online tool allows to use Z-scores for DMT decisions in daily practice. Can we now flip and zip the DMT pyramid? multiple-sclerosis-research.…
3
We cannot prescribe anti-CD20 indefinitely, and there’s considerable evidence to start using it as an induction therapy. Understandably, many pwMS are not prepared to let go of the 6-monthly infusions. Would you be prepared to stop? @the_MSBlog multiple-sclerosis-research.…
3
2
13
PwMS who smoke are more susceptible to worsening motor and walking function and have higher anxiety levels. More importantly, pwMS who manage to quit smoking behave like non-smokers. How do we open the window for smoking cessation among pwMS? @the_MSBlog multiple-sclerosis-research.…
1
4
1
17
Anti-CD20 side effects become more frequent with longstanding use. By following our 5 derisking steps, we aim to protect pwMS from unwanted side effects. Is your mind ready for prevention? multiple-sclerosis-research.…
5
When flaws are aligned, runners get hit by a car and elbows are fractured. As soon as it happens, we want to forget about it making it difficult to ask the right questions. This is exactly why we designed the DMT tool for pwMS facing treatment decisions.multiple-sclerosis-research.…
1
3
Annual MRI scans are an anxiety-provoking routine, and new lesions leave pwMS torn between ‘one is none’ vs ‘my brain is on fire’. Together with @danielsaloreich and @GavinGiovannoni we put the facts in a row, and help pwMS read between the lesions! multiple-sclerosis-research.…
1
5
25
The ideal situation for female pwMS who want to complete their family is to be ‘DMT-free’. This can only be achieved by choosing early for an induction therapy, irrespective of having mild vs. severe MS. multiple-sclerosis-research.… @the_MSBlog
2
4
MS progressively becomes more invisible at older age, and many neurologists struggle with the risk vs. benefits of initiating a treatment. Time for a grey pride movement? multiple-sclerosis-research.…
1
6
In MS, you have first (medium efficacy, favourable side effect profile) and second line (high efficacy) DMTs. However, some DMTs are not be boxed, and represent a new species: efficacy sheep in wolf’s clothing. multiple-sclerosis-research.… @the_MSBlog
3
Does true patient consent exist when participating in research studies? No, I feel it’s rather a matter of trust and novelty. People tend not to read consent forms and if they do, they do not fully understand the content. Do you disagree? multiple-sclerosis-research.… @the_MSBlog
1